{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:42:08Z","timestamp":1782175328290,"version":"3.54.5"},"reference-count":57,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000},"content-version":"vor","delay-in-days":1760,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2001,4]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> Studies concerning the treatment of substance\u2010abusing suicidal patients are scarce despite the frequent presence of suicidal behavior among this population. Indeed, suicidality (ideation or behavior) is generally an exclusion criterion for participation in treatment studies of subjects with alcohol or drug abuse. Consequently, to date, little is known about the optimal treatment of this population. The first study involving substance\u2010abusing suicidal patients was an open\u2010label trial conducted in the early 1990s. This study involved 12 patients, all of whom demonstrated recent suicidal ideations and had made a lifetime suicide attempt. The results of that open\u2010label study demonstrated significant within\u2010group improvement in both depressive symptoms (including suicidal ideations) and level of drinking. However, substantial residual depressive symptoms and drinking persisted at the end of the trial. Also, because no placebo control group was utilized, the authors of that study could not rule out the possibility that the apparent therapeutic effect from fluoxetine was the result of the placebo effect. To date, only one double\u2010blind, placebo\u2010controlled study of subjects with alcohol or substance abuse has included substantial numbers of suicidal patients. The study involved 51 subjects, of whom 20 (39%) had made a suicide attempt in the current depressive episode, 31 (61%) had made a suicide attempt in their lifetime, and 46 (90%) had reported suicidal ideations in the week before hospitalization. The results of that double\u2010blind, placebo\u2010controlled study suggest that fluoxetine was effective in decreasing but not eliminating both the depressive symptoms (including suicidal ideations) and the level of alcohol consumption among a study group of subjects with comorbid major depressive disorder and alcohol dependence, many of whom displayed suicidal ideations. A secondary data analysis from that study suggested that cigarette smoking is also significantly decreased by fluoxetine, but the magnitude of the decrease is limited and few of these patients totally quit smoking with fluoxetine treatment alone. Another secondary data analysis from that study suggested that marijuana smoking was also significantly decreased in a subgroup of subjects who demonstrated cannabis abuse and that the magnitude of this improvement was robust. A third secondary data analysis from that study suggested that cocaine abuse acts as a predictor of poor outcome for both depressive symptoms (including suicidality) and level of alcohol use in this population. The results of a 1\u2010year naturalistic follow\u2010up study involving the patients from that study suggest that the benefits of fluoxetine in decreasing depressive symptoms and level of drinking persist 1 year after entering the treatment program. To date, no other double\u2010blind, placebo\u2010controlled studies involving substantial numbers of substance\u2010abusing suicidal patients have been reported to either confirm or refute these findings. Further studies are clearly warranted to evaluate the efficacy of various pharmacotherapeutic agents and various psychotherapies in the treatment of substance\u2010abusing suicidal patients.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2001.tb05799.x","type":"journal-article","created":{"date-parts":[[2010,7,20]],"date-time":"2010-07-20T20:56:59Z","timestamp":1279659419000},"page":"78-93","source":"Crossref","is-referenced-by-count":13,"title":["Treating the Substance\u2010Abusing Suicidal Patient"],"prefix":"10.1111","volume":"932","author":[{"given":"Jack R.","family":"Cornelius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihsan M.","family":"Salloum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan B.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. John","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.125.4.355"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1943-278X.1986.tb00354.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.144.2.208"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.15288\/jsa.1988.49.436"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.6.935"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950190076011"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.2.3.244"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.8.1009"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.8.1001"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.15288\/jsa.1988.49.219"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450190043026"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950010008002"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830160031005"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.7.1063"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.15288\/jsa.1980.41.672"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1984.01790200070009"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820060039006"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.147.6.761"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1996.tb01148.x"},{"key":"e_1_2_6_21_2","first-page":"3","article-title":"Alcoholism, alcohol, and attempted suicide","volume":"24","author":"Hawton K.","year":"1989","journal-title":"Alcohol Alcohol"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0010-440X(93)90017-X"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.3.358"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(95)90251-1"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(95)90070-5"},{"key":"e_1_2_6_26_2","unstructured":"Cornelius J.R. I.M. Salloum D.C. Daley et al.1996. Clinical profile and evaluation of comorbid major depression and alcoholism.InTreating Substance Abuse Part II. J. Lonsdale ed. :119\u2010137. Hatherleigh Press. New York NY."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(96)90569-6"},{"key":"e_1_2_6_28_2","first-page":"165","article-title":"Double\u2010blind fluoxetine in depressed alcoholic smokers","volume":"33","author":"Cornelius J.R.","year":"1997","journal-title":"Psychopharmacol. Bull"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199301000-00012"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.15288\/jsa.1999.60.422"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.15288\/jsa.1986.47.78"},{"key":"e_1_2_6_32_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00782961","article-title":"An epidemiologic investigation of potential risk factors","volume":"25","author":"Petronis K.R.","year":"1990","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4603(97)00019-1"},{"key":"e_1_2_6_34_2","first-page":"255","article-title":"Age of alcoholism onset","volume":"46","author":"Buydens\u2010Branchey L.","year":"1989","journal-title":"I. Relationship to psychopathology. Arch. Gen. Psychiatry"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.55.3.259"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1985.tb05744.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1987.01800180015002"},{"key":"e_1_2_6_38_2","unstructured":"Brady K.T. P. Halligan & R.J. Malcolm. 1999. Dual diagnosis.InTextbook of Substance Abuse Treatment 2nd Ed. M. Galanter & H.D. Kleber eds. : 475\u2010483. The American Psychiatric Press. Washington DC."},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830200024004"},{"key":"e_1_2_6_40_2","first-page":"195","article-title":"Fluoxetine trial in suicidal depressed alcoholics","volume":"29","author":"Cornelius J.R.","year":"1993","journal-title":"Psychopharmacol. Bull"},{"key":"e_1_2_6_41_2","doi-asserted-by":"crossref","unstructured":"Cornelius J.R. I.M. Salloum R.F. Haskett et al.2000. Fluoxetine versus placebo in depressed alcoholics: a one\u2010year follow\u2010up study. Addict. Behav.25:307\u2013310.","DOI":"10.1016\/S0306-4603(99)00065-9"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00509-X"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.3.391"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.62"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830030054009"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1995.tb01532.x"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530340025025"},{"key":"e_1_2_6_48_2","first-page":"31","article-title":"Fluoxetine treatment of cocaine abuse in heroin addicts","volume":"52","author":"Pollack M.H.","year":"1991","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1997.7.87"},{"key":"e_1_2_6_50_2","first-page":"117","article-title":"Fluoxetine versus placebo in depressed alcoholic cocaine abusers","volume":"34","author":"Cornelius J.R.","year":"1998","journal-title":"Psychopharmacol. Bull"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199904000-00015"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4603(98)00050-1"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1996.tb01185.x"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1998.tb03912.x"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.04390010030004"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.1996.tb00316.x"},{"key":"e_1_2_6_57_2","first-page":"111","article-title":"Naltrexone utility in depressed alcoholics","volume":"34","author":"Salloum I.M.","year":"1998","journal-title":"Psychopharmacol. Bull"},{"key":"e_1_2_6_58_2","first-page":"239","article-title":"Double\u2010blind randomized multicenter trial of acamprosate in maintaining abstinence from alcohol","volume":"30","author":"Paille F.M.","year":"1995","journal-title":"Alcohol Alcohol"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2001.tb05799.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2001.tb05799.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T08:50:37Z","timestamp":1695631837000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2001.tb05799.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,4]]}},"alternative-id":["10.1111\/j.1749-6632.2001.tb05799.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2001.tb05799.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,4]]}}}